Changing the Course of Cancer Treatment

AdvanCell is a clinical stage radiopharmaceutical company developing treatments to significantly improve survival and quality of life for patients with cancer.

Play Video

Development Pipeline

AdvanCell is delivering a portfolio of therapies to market for the treatment of prostate cancer, melanoma, pancreatic cancer, breast cancer and colorectal cancer.

Groundbreaking Technology


Proprietary ²¹²Pb production technology provides access to an unmatched supply of alpha isotopes to accelerate clinical development of a portfolio of targeted alpha therapies.

Read more

Alpha 212 is the product of AdvanCell’s ²¹²Pb generator. It is a quality-controlled dose of ²¹²Pb as an Active Pharmaceutical Ingredient (API) manufactured to international GMP standards.

Read more